Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Paul R. Buckley


Postdoctoral Researcher

Paul R. Buckley is a Postdoctoral Researcher in the Koohy and Cerundolo labs, in the MRC Human Immunology Unit at the Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital. His research is focused on exploring the mechanisms underlying the heterogeneity in patient responses to cancer immunotherapies such as anti-CTLA-4 and anti-PD1. 

After completion of a BSc in Computer Forensics and IT Security and working in Computer Networking in London, Paul completed a MSc in Bioinformatics with Systems Biology at Birkbeck, University of London. He then went on to the University of York, where he began his PhD before moving to The Kennedy Institute of Rheumatology, University of Oxford where he completed his DPhil in Molecular Medicine with Prof. Mark Coles (Oxford) and Prof. Jon Timmis (York). His DPhil research focused on utilising mechanistic modelling to explore how vaccine adjuvants - specifically AS01 - initiate immune responses in murine draining lymph nodes. This work resulted in the development of a modelling framework for the application of mechanistic modelling to explore adjuvant mechanism of action (MoA), as well as the first holistic model of AS01's MoA. In addition, models and simulations of adjuvant-induced immune responses that were developed as part of his DPhil have resulted in novel immunological insight and hypotheses. During his DPhil research he worked closely with GSK Vaccines (Belgium and Italy), who develop AS01 and the corresponding vaccines in which AS01 is employed.

In October 2019, he moved to the WIMM, Radcliffe Department of Medicine, where he is using computational modelling and machine-learning to further the understanding of heterogeneity in patient responses to cancer immunotherapies. Paul is a passionate advocate of the application and development of 3Rs techniques in immunology so to reduce, refine and replace the use of animals in research.